Initially, the recurrent rearrangements including BCR-ABL, AML1-ETO, TEL-AML1, and TML-RARA were used with conventional technologies such as reverse-transcription polymerase chain reaction (RT-PCR) to monitor minimal residual tumors and classify hematologic malignancies [1], [4], [5]. This evidence concerns the gene RUNX1 and hematologic disorder.